UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC Has $41.16 Million Stake in Insmed, Inc. $INSM

Key Points

• UBS Asset Management increased its stake in Insmed, Inc. by 10.8%, now owning approximately $41.16 million worth of shares, totaling 539,484 shares.
• Several brokerages have upgraded Insmed's stock rating, with price targets raised significantly, including Wells Fargo increasing their target from $140 to $171.
• Insmed's latest earnings report showed a revenue increase of 18.9% year-over-year, while the company reported a higher-than-expected loss of $1.70 EPS.

UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its position in Insmed, Inc. (NASDAQ:INSM - Free Report) by 10.8% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 539,484 shares of the biopharmaceutical company's stock after buying an additional 52,637 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC owned approximately 0.30% of Insmed worth $41,157,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Cullen Frost Bankers Inc. raised its holdings in shares of Insmed by 164.9% during the first quarter. Cullen Frost Bankers Inc. now owns 355 shares of the biopharmaceutical company's stock valued at $27,000 after purchasing an additional 221 shares during the period. Elequin Capital LP acquired a new position in shares of Insmed during the fourth quarter valued at about $28,000. NBC Securities Inc. acquired a new position in shares of Insmed during the first quarter valued at about $49,000. Versant Capital Management Inc raised its holdings in shares of Insmed by 546.3% during the first quarter. Versant Capital Management Inc now owns 698 shares of the biopharmaceutical company's stock valued at $53,000 after purchasing an additional 590 shares during the period. Finally, Signaturefd LLC raised its holdings in shares of Insmed by 60.0% during the first quarter. Signaturefd LLC now owns 867 shares of the biopharmaceutical company's stock valued at $66,000 after purchasing an additional 325 shares during the period.

Analyst Upgrades and Downgrades

Several brokerages have recently weighed in on INSM. Wells Fargo & Company upped their price objective on shares of Insmed from $140.00 to $171.00 and gave the company an "overweight" rating in a report on Wednesday, September 3rd. Citigroup upgraded shares of Insmed to a "buy" rating in a report on Tuesday, June 10th. Truist Financial upped their target price on shares of Insmed from $126.00 to $139.00 and gave the stock a "buy" rating in a report on Thursday, August 14th. Royal Bank Of Canada upped their target price on shares of Insmed from $108.00 to $120.00 and gave the stock an "outperform" rating in a report on Friday, August 8th. Finally, JPMorgan Chase & Co. upped their target price on shares of Insmed from $111.00 to $135.00 and gave the stock an "overweight" rating in a report on Wednesday, August 20th. Sixteen analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company's stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $139.86.

Insider Buying and Selling at Insmed

In related news, CFO Sara Bonstein sold 58,400 shares of the business's stock in a transaction dated Monday, July 21st. The shares were sold at an average price of $102.67, for a total transaction of $5,995,928.00. Following the sale, the chief financial officer owned 73,505 shares of the company's stock, valued at $7,546,758.35. The trade was a 44.27% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Michael Alexander Smith sold 24,272 shares of the company's stock in a transaction that occurred on Tuesday, September 2nd. The stock was sold at an average price of $143.89, for a total transaction of $3,492,498.08. Following the completion of the transaction, the insider owned 54,902 shares in the company, valued at approximately $7,899,848.78. This represents a 30.66% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 248,577 shares of company stock valued at $27,137,914 over the last three months. 3.00% of the stock is currently owned by corporate insiders.

Insmed Stock Up 0.1%

Shares of NASDAQ:INSM opened at $145.93 on Monday. The company has a market cap of $30.85 billion, a price-to-earnings ratio of -25.56 and a beta of 0.97. The firm has a fifty day moving average price of $119.40 and a two-hundred day moving average price of $92.09. Insmed, Inc. has a one year low of $60.40 and a one year high of $149.08. The company has a debt-to-equity ratio of 0.45, a current ratio of 6.68 and a quick ratio of 6.33.

Insmed (NASDAQ:INSM - Get Free Report) last issued its earnings results on Thursday, August 7th. The biopharmaceutical company reported ($1.70) EPS for the quarter, missing analysts' consensus estimates of ($1.30) by ($0.40). The business had revenue of $107.42 million during the quarter, compared to analysts' expectations of $104.06 million. Insmed had a negative return on equity of 195.37% and a negative net margin of 259.82%.Insmed's revenue for the quarter was up 18.9% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($1.94) EPS. Insmed has set its FY 2025 guidance at EPS. Analysts anticipate that Insmed, Inc. will post -4.56 EPS for the current fiscal year.

About Insmed

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.

Want to see what other hedge funds are holding INSM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Insmed, Inc. (NASDAQ:INSM - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.